The £1 Pill That Could Transform Cancer Care
How low-dose aspirin halves colorectal cancer recurrence for patients with key genetic mutations
Why it matters
A single daily tablet costing less than 10p has delivered one of the most remarkable breakthroughs in modern oncology. The ALASCCA trial, published in the New England Journal of Medicine in September 2025, shows that low-dose aspirin can cut the recurrence of colorectal cancer by around 50 per cent in patients carrying specific PI3K-pathwa…
Keep reading with a 7-day free trial
Subscribe to The Control Layer to keep reading this post and get 7 days of free access to the full post archives.